Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

EU Com­mis­sion Fol­lows CHMP Rec­om­men­da­tion: Boost­er Vac­ci­na­tion with COVID-19 Vac­cine Comir­naty for Chil­dren and Ado­les­cents 12 years and up

On 01 March 2022 the EU Commission agreed to extend the authorisation of the vaccine Comirnaty (BioNTech/Pfizer) to include booster vaccination for children and adolescents aged 12 years and older. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) recommended this course of action on 24 February 2022.

COVID-19 vaccine Comirnaty ampoules next to vaccination card and syringe (Source: r.classen/Shutterstock.com)

Booster vaccinations are given to fully vaccinated individuals (i.e. individuals who have completed primary vaccination) to maintain or restore immunity after it has waned.

Booster vaccination with Comirnaty had previously only been authorised for individuals 18 years of age and older.

Safety and efficacy data

The CHMP recommendation underlying the EU Commission's decision is based on the assessment of all available data on safety, immunogenicity, and efficacy of both of the initial vaccinations and of the booster dose across the different age groups. In addition, findings from the use of booster vaccinations among adolescents in Israel and adults worldwide were considered for the recommendation.

Updated: 01.03.2022